The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive…

AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?
Fernando Munoz, Francesco Fiorica
Frontiers in oncology5 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMCCrossref
Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
EClinicalMedicine1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
[¹⁷⁷Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Carlo Buonerba, Giuseppe Di Lorenzo
Current oncology (Toronto, Ont.)16 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMCDOAJ
Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.
Galip Can Uyar, Kadriye Başkurt, Orhun Akdoğan +8
The oncologist1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer.
Georges Gebrael, Yeonjung Jo, Varun Nandakumar +14
JAMA network open1 Oct 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCCrossref

Cite

BibTeX

@article{anon2026role,
  title = {{The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer}},
  journal = {Biomedicines},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13701217},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer
PY  - 2026
DA  - 2026/09/24
JO  - Biomedicines
UR  - https://europepmc.org/article/PMC/PMC13701217
SN  - 2227-9059
ER  -

Related

Cite